Haihong Jin

Haihong Jin's work experience includes serving as an Associate Director at Seed Therapeutics since August 2022. Prior to that, they worked as a Principal Scientist at Atomwise starting in October 2020. From 2015 to their time at Atomwise, they were an Associate Director at OHSU | Oregon Health & Science University. At OHSU, they managed the Medicinal Chemistry Core, invented novel MR1 ligands, developed immunomodulatory small molecules, and optimized IRF 3 activators, among other achievements. Before working at OHSU, Haihong Jin was a Sr. Research Scientist at Lexicon Pharmaceuticals from 2000 to 2011, where they co-invented Orphan Drug XERMELO and demonstrated efficacy in phase 2 clinical trials for irritable bowel syndrome. Haihong also worked as a Senior Development Chemist at Chemtura Corporation from 1996 to 2000.

Haihong Jin completed a Bachelor's degree in Fine Chemical Engineering at East China University of Science and Technology in Shanghai, China from 1986 to 1990. Haihong then pursued a Master's degree in Organic Chemistry at the same institution from 1990 to 1992. Following that, Haihong Jin enrolled at the University of Connecticut, where they obtained a Doctor of Philosophy (PhD) in Organic Chemistry from 1992 to 1999.